Skip to main content
. 2024 May 22;630(8015):166–173. doi: 10.1038/s41586-024-07465-2

Fig. 2. Major changes in hepatocyte zonation and biliary-tree remodelling in end-stage MASLD.

Fig. 2

a, UMAP of hepatocytes annotated by disease stage. b, Correlation analysis examining expression of pericentral and periportal hepatocyte markers across disease progression. c, Immunofluorescence staining for pericentral marker GLUL, periportal marker ASS1 and pan-hepatocyte marker ALB in healthy and end-stage MASLD tissue sections. The yellow dashed arrow indicates the central vein; n = 3 healthy and n = 3 end-stage tissue samples. Scale bars: 50 μm (healthy) and 10 μm (end stage). d, 3D projections of cleared healthy and end-stage MASLD liver samples. Staining with K7 for cholangiocytes and MRP2 for hepatocytes; n = 3 healthy and n = 3 end-stage tissue samples. Scale bars: 100 μm (healthy), 50 μm (end stage). e, The area in the yellow box (left) is shown in higher magnification in the other three boxes, highlighting an example of a MRP2–K19 co-positive cell at the end of a duct; n = 3 healthy and n = 3 end-stage tissue samples. Scale bars: 30 μm (left), 10 μm (the other panels). See also Supplementary Videos 3 and 4.